| Primary |
| T-cell Type Acute Leukaemia |
67.7% |
| Non-hodgkin's Lymphoma |
8.0% |
| Acute Lymphocytic Leukaemia |
6.2% |
| T-cell Lymphoma |
3.4% |
| Lymphocytic Leukaemia |
2.8% |
| Infection Prophylaxis |
2.3% |
| Product Used For Unknown Indication |
2.1% |
| Bone Marrow Transplant |
1.6% |
| Recurrent Cancer |
1.4% |
| Disease Recurrence |
0.9% |
| Hypertension |
0.7% |
| Haematological Malignancy |
0.5% |
| Headache |
0.5% |
| Sepsis |
0.5% |
| Tumour Lysis Syndrome |
0.5% |
| Antifungal Prophylaxis |
0.2% |
| Antipyresis |
0.2% |
| Drug Use For Unknown Indication |
0.2% |
| Leukaemia |
0.2% |
| Mediastinal Mass |
0.2% |
|
| Sepsis |
12.9% |
| Spinal Cord Ischaemia |
9.7% |
| Rhabdomyolysis |
8.1% |
| Aspartate Aminotransferase Increased |
6.5% |
| Multi-organ Failure |
6.5% |
| Leukocytosis |
4.8% |
| Somnolence |
4.8% |
| Upper Respiratory Tract Infection |
4.8% |
| Urinary Incontinence |
4.8% |
| Urinary Retention |
4.8% |
| Aphasia |
3.2% |
| Asthenia |
3.2% |
| Convulsion |
3.2% |
| Disease Progression |
3.2% |
| Hypersensitivity |
3.2% |
| Myositis |
3.2% |
| Neuropathy Peripheral |
3.2% |
| Paraesthesia |
3.2% |
| Tachycardia |
3.2% |
| Vomiting |
3.2% |
|
| Secondary |
| T-cell Lymphoma |
25.7% |
| Acute Lymphocytic Leukaemia |
20.2% |
| Non-hodgkin's Lymphoma |
16.5% |
| Bone Marrow Transplant |
11.0% |
| Prophylaxis Against Graft Versus Host Disease |
8.3% |
| Lymphocytic Leukaemia |
6.4% |
| T-cell Type Acute Leukaemia |
5.5% |
| Antiviral Prophylaxis |
2.8% |
| Graft Versus Host Disease |
2.8% |
| Nervous System Disorder |
0.9% |
|
| Bone Marrow Failure |
13.0% |
| Disease Progression |
13.0% |
| Leukoencephalopathy |
8.7% |
| Pleural Effusion |
8.7% |
| Stevens-johnson Syndrome |
8.7% |
| Viral Haemorrhagic Cystitis |
8.7% |
| Cystitis Haemorrhagic |
4.3% |
| Guillain-barre Syndrome |
4.3% |
| Mediastinal Mass |
4.3% |
| Partial Seizures |
4.3% |
| Sepsis |
4.3% |
| Skin Erosion |
4.3% |
| T-cell Lymphoma |
4.3% |
| T-cell Lymphoma Stage Iii |
4.3% |
| Therapeutic Response Decreased |
4.3% |
|
| Concomitant |
| Prophylaxis Against Graft Versus Host Disease |
32.9% |
| Bone Marrow Conditioning Regimen |
25.3% |
| Acute Lymphocytic Leukaemia Recurrent |
11.4% |
| Acute Lymphocytic Leukaemia |
8.9% |
| Infection Prophylaxis |
5.1% |
| Stem Cell Transplant |
5.1% |
| Allogenic Bone Marrow Transplantation Therapy |
2.5% |
| Product Used For Unknown Indication |
2.5% |
| T-cell Chronic Lymphocytic Leukaemia |
2.5% |
| Brain Neoplasm |
1.3% |
| Non-hodgkin's Lymphoma |
1.3% |
| T-cell Lymphoma |
1.3% |
|
| Drug Ineffective |
17.6% |
| Respiratory Disorder |
17.6% |
| Urinary Retention |
17.6% |
| Viith Nerve Paralysis |
11.8% |
| Disease Progression |
5.9% |
| Malignant Neoplasm Progression |
5.9% |
| Mucosal Inflammation |
5.9% |
| Off Label Use |
5.9% |
| Somnolence |
5.9% |
| Venoocclusive Liver Disease |
5.9% |
|
